Journey Medical Corp (DERM): debt financing — Journey Medical extends term loan maturity to June 2028 and lowers revenue threshold for deferred repayment to $60M

Journey Medical Corp

Maturity of $25M Term Loan extended from Dec 27, 2027 to June 27, 2028.
If trailing 12-month revenue > $60M as of Dec 31, 2025 (down from $70M), principal repayment deferred to Feb 2027.
Without revenue trigger, quarterly repayment begins Feb 2026 at 7.5% of principal.
With revenue trigger, quarterly repayment at 10% starting Feb 2027 (down from 15%).
All $25M drawn; agreement amended with SWK Funding LLC.

item 1.01 item 2.03

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Journey Medical Corp amended term loan of $25.0 million with SWK Funding LLC maturing June 27, 2028.

Instrument: term loan
Principal: $25.0 million
Counterparty: SWK Funding LLC
Maturity: June 27, 2028
Event: amendment

Exact text from the filing

October 21, 2024 and the Third Amendment, the “Amended Credit Agreement”). The Amended Credit Agreement provides for a term loan facility in the original principal amount of $25.0 million. As of the date of this report, the Company has drawn the full $25.0 million, which is treated under the Amended Credit Agreement as a single loan (the “Term Loan”). The Third

View on SEC.gov

Browse all debt financings →

Journey Medical Corp filing history →

Source: SEC EDGAR

accession 0001104659-25-093891

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.